eng
  • kor
  • eng
  • chn
  • esp
topBtn
News
News

VXCAD-CXR, an AI diagnostic aid solution for chest, receives approval from the Ministry of Food and Drug Safety

2024-08-20

- VXCAD-CXR, a diagnostic aid solution, detects 3 major chest diseases with artificial intelligence

- Achieved an AUROC of 0.98 or higher for diagnosing 3 types of chest diseases

- Plans to expand diagnostic scope to consolidation and pneumonia





Vieworks, the leading provider of imaging solution, has successfully developed and licensed a diagnostic aid solution optimized for its X-ray detector, further strengthening its capabilities in convergence medical imaging solutions.
 

Vieworks announced on the 20th that it has acquired MFDS(Ministry of Food and Drug Safety) certification for VXCAD-CXR, an artificial intelligence-based chest diagnostic aid solution developed by the company's affiliated research institute.
 

VXCAD-CXR is an artificial intelligence-based diagnostic aid that analyzes chest radiography images and automatically suggests areas of suspected disease and the probability of abnormalities. It provides information on the probability of occurrence and lesion site for three major chest diseases, Pleural Effusion, Pneumothorax, and Nodules, enabling medical staff to provide immediate results on-site.
 

The Area Under ROC curve (AUROC), a typical metric for evaluating the performance of diagnostic assistant solutions, showed high accuracy for detection of Pleural Effusion at 0.9993, Pneumothorax at 0.9959, and Nodules at 0.9846. In general, the closer the AUROC is to 1, the higher the diagnostic accuracy. In the future, we plan to increase the number of diagnosable lesions, including Consolidation and Pneumonia, through additional data learning.
 

With this, Vieworks will focus on building an integrated medical imaging solution that provides clear images with ultra-small pixels and AI-based diagnostic aids. “We will increase our market share by showcasing our existing hardware strengths, such as X-ray detectors, along with diagnostic aids optimized for them,” said a Vieworks representative.
 

Meanwhile, Vieworks will continue to diversify its lineup of diagnostic aid solutions, starting with the acquisition of the domestic license for VXCAD-CXR. This year, the company will introduce CAD (Computer-aided Diagnostics), which enables computer programs to provide opinions on diseases, as well as two deep learning-based noise reduction technologies that enable clearer images with lower doses, enhancing the convenience and safety of medical staff.
 

In line with the increasing demand for emergency medical services and the sophisticated healthcare market, developing AI-based diagnostic aids for medical device companies is becoming a necessity, not an option. We will continue to create high added value and innovate medical imaging solutions using our in-house development capabilities as a driving force.” said Hooshik Kim, CEO of Vieworks.


  • Listlist
  • Korean
  • English
  • Chinese
English